Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture
References (10)
- et al.
Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-inethylglutaryl coenzyme A reductase
Biochim Biophys Acta
(1990) - et al.
CS-514, a competitive inhibitor of 3-hydroxy-3-inethylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
Biochim Biophys Acta
(1986) - et al.
Isolation and use of liver cells
Methods Enzymol
(1978) - et al.
Protein measurement with the Folin phenol reagent
J Biol Chem
(1951) - et al.
ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by penicillium citrinum
J Antibiot
(1976)
There are more references available in the full text version of this article.
Cited by (71)
The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides
2010, Drug Metabolism and PharmacokineticsStatin effects on cholesterol micro-domains in brain plasma membranes
2003, Biochemical PharmacologyCitation Excerpt :While simvastatin and lovastatin as lipophilic lactone pro-drugs [19] are assumed to affect the central nervous system by penetrating the BBB [20,21], pravastatin does not enter the brain [22]. In the periphery, pravastatin utilises active transport mechanisms for membrane passage [23]. Since the compound is undetectable in the CSF of healthy subjects [22], one might doubt that similar transport systems occur at the BBB.
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
2004, Clinical Pharmacology and TherapeuticsMicrofluidic technology and simulation models in studying pharmacokinetics during pregnancy
2023, Frontiers in PharmacologyDisaccharides obtained from carrageenans as potential antitumor agents
2019, Scientific Reports
Copyright © 1992 Published by Elsevier Inc.